Flortaucipir f-18 - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for flortaucipir f-18 and what is the scope of patent protection?
Flortaucipir f-18
is the generic ingredient in one branded drug marketed by Avid Radiopharms Inc and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.Flortaucipir f-18 has twenty-six patent family members in sixteen countries.
One supplier is listed for this compound.
Summary for flortaucipir f-18
| International Patents: | 26 |
| US Patents: | 1 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 4 |
| Clinical Trials: | 21 |
| Patent Applications: | 18 |
| What excipients (inactive ingredients) are in flortaucipir f-18? | flortaucipir f-18 excipients list |
| DailyMed Link: | flortaucipir f-18 at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for flortaucipir f-18
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for flortaucipir f-18
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Neuroscience Trials Australia | Phase 2 |
| Tharick Pascoal | Phase 1 |
| Seelos Therapeutics, Inc. | Phase 2 |
US Patents and Regulatory Information for flortaucipir f-18
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avid Radiopharms Inc | TAUVID | flortaucipir f-18 | SOLUTION;INTRAVENOUS | 212123-002 | May 28, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Avid Radiopharms Inc | TAUVID | flortaucipir f-18 | SOLUTION;INTRAVENOUS | 212123-004 | Jul 1, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Avid Radiopharms Inc | TAUVID | flortaucipir f-18 | SOLUTION;INTRAVENOUS | 212123-001 | May 28, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Avid Radiopharms Inc | TAUVID | flortaucipir f-18 | SOLUTION;INTRAVENOUS | 212123-002 | May 28, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Avid Radiopharms Inc | TAUVID | flortaucipir f-18 | SOLUTION;INTRAVENOUS | 212123-001 | May 28, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
